International Conference on the Holocaust and Genocide

We Are "One!" 1,400 Proud Zionists Unite at Jewish National Fund-USA's National Conference

Retrieved on: 
Montag, November 14, 2022
Quality of life, Ecology, Conference, Muss, Refugee, Farmer, Jews, The Next Decade (book), Student, International Conference on the Holocaust and Genocide, Friends of the Israel Defense Forces, Partnership, Hearing, Intellectual disability, Shark Tank, Multimedia, Jewish National Fund, Disability, National Conference, Alexander Muss High School in Israel, Employment, Medicine, Renewable energy, Zionism

BOSTON, Nov. 14, 2022 //PRNewswire// -- Over 1,400 supporters of the land and people of Israel united in Boston on November 4-6, 2022, for an unforgettable and riveting weekend at Jewish National Fund-USA's largest ever National Conference .

Key Points: 
  • BOSTON, Nov. 14, 2022 //PRNewswire// -- Over 1,400 supporters of the land and people of Israel united in Boston on November 4-6, 2022, for an unforgettable and riveting weekend at Jewish National Fund-USA's largest ever National Conference .
  • "We are particularly proud of the role Jewish National Fund-USA continues to play in broadening and deepening the people-to-people connection between Israel and the U.S.," said Boston-based philanthropists and National Conference Co-Chairs, Risa Aronson and Michael Blank.
  • Jewish National Fund-USA's National Conference also welcomed over 600 high school and college students from across the country.
  • Registration is open for Jewish National Fund-USA's 2023 International Conference for Israel (November 30-December 3, 2023) in Denver, Colorado.

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Montag, August 15, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ino, U.S. Securities and Exchange Commission, Survival, Trial of the century, Private Securities Litigation Reform Act, GLOBE, Diagnosis, Clinical trial, Poster, MVPA, Security (finance), Annual report, Annals of the American Thoracic Society, ST, PVR, Public expenditure, Patient, Therapy, Company, International Conference on the Holocaust and Genocide, Safety, Paul Fildes, Research, Sarcoidosis, University, Tesa SA, Nasdaq, Pulmonary hypertension, Conference, Hepatic artery proper, Food, Pharmaceutical industry, Aquaculture, Medicine, Bellerophon

WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022.

Key Points: 
  • WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022.
  • REBUILD Phase 3 Study: Enrollment is continuing in Bellerophons Phase 3 REBUILD registrational study of INOpulse for the treatment of fILD.
  • The Phase 3 program builds on positive top-line results from the Companys previously reported Phase 2 studies for INOpulse for the treatment of fILD.
  • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty

Retrieved on: 
Freitag, August 13, 2021
Forward-looking statement, Intussusception (medical disorder), Clinical trial, Muscle, ADL, Calendar, Observation, HLHS, CGMP, NIA, Emax, Safety, Pros, National Institute on Aging, Company, SBIR, Risk, SEC, Miami, Telephone, FDA, Fear, Cognition, Particle-size distribution, Depression, Weight loss, Inflammation, Infection, Population, Adult, Walking, CEO, Microsoft, Goal, Patent, Intention, Cell, Small Business Innovation Research, Fatigue, Conference, Metabolic syndrome, Bone marrow, National academy, Malnutrition, Physician, International Conference on the Holocaust and Genocide, Hospital, NASDAQ, Terminology, Serum, Hypoplastic left heart syndrome, Disorder, National Academy of Medicine, Linearity, National Institute, Education, Program, Immune system, GLOBE, CHSA, Medical imaging, Pharmaceutical industry, Fertilizer

MIAMI, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced results from the Company’s Phase 2b trial titled: A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B Infusion in Patients With Aging Frailty (the “Phase 2b trial”). Lomecel-B is a proprietary allogeneic product comprised of medicinal signaling cells (MSCs) from the bone marrow of adult donors and culture-expanded in Longeveron’s current good manufacturing practice (cGMP) cell processing facility. The Phase 2b trial, which was partially funded by a Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA), evaluated the safety and efficacy of a single peripheral intravenous infusion of four different doses of Lomecel-B cell therapy (25 million (n=37), 50 million (n=31), 100 million (n=34) and 200 million (n=16) cells; sample size reflects any subject that was randomized and received an infusion) compared to placebo (n=30), on signs and symptoms of Aging Frailty, including mobility and exercise tolerance.

Key Points: 
  • About the US Phase 2b Aging Frailty Trial:
    The primary objective of this multi-center study is to assess the effect of Lomecel-B on exercise tolerance and endurance via the six-minute walk test (6MWT).
  • Aging Frailty is a life-threatening geriatric condition affecting approximately 15% of Americans over the age of 65, or 8.1 million individuals.
  • The necessity for identifying patients with Aging Frailty is well-acknowledged in the geriatric community, and the treatment of Aging Frailty and promotion of healthful aging are recognized priorities of the National Academy of Medicine and NIA/NIH.
  • Despite the pressing need for interventions, there are no FDA-approved therapies that can slow down, reverse, or prevent Aging Frailty.